Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China


SAN DIEGO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today announced the approval from the National Medical Products Administration (NMPA) of China to initiate the Phase 3 clinical trial of LBS-008 in adolescent STGD1 in China.

See the original post:
Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China

Related Posts